MedPath

UNIVERSITY OF ILLINOIS

UNIVERSITY OF ILLINOIS logo
🇺🇸United States
Ownership
Private
Established
1859-01-01
Employees
10K
Market Cap
-
Website
http://www.illinois.edu

Clinical Trials

471

Active:36
Completed:246

Trial Phases

6 Phases

Early Phase 1:9
Phase 1:34
Phase 2:41
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (427 trials with phase data)• Click on a phase to view related trials

Not Applicable
311 (72.8%)
Phase 2
41 (9.6%)
Phase 1
34 (8.0%)
Phase 4
21 (4.9%)
Phase 3
11 (2.6%)
Early Phase 1
9 (2.1%)

Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

Not Applicable
Not yet recruiting
Conditions
Albuminuria
Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
Interventions
First Posted Date
2025-09-16
Last Posted Date
2025-09-16
Lead Sponsor
University of Illinois at Chicago
Target Recruit Count
20
Registration Number
NCT07175051
Locations
🇺🇸

University of Illinois Chicago, Sickle Cell Center, Chicago, Illinois, United States

A Community Engagement Approach to Improving Communication With Black Men About Oral and Pharyngeal Cancers

Not Applicable
Not yet recruiting
Conditions
Oral Cancers
First Posted Date
2025-09-15
Last Posted Date
2025-09-15
Lead Sponsor
University of Illinois at Chicago
Target Recruit Count
50
Registration Number
NCT07172776

Synergistic Minimally Invasive Surgery Plus Alteplase and Deferoxamine in ICH

Not Applicable
Not yet recruiting
Conditions
Intracerebral Hemorrhage
ICH - Intracerebral Hemorrhage
Interventions
Other: Standard Medical Care (SMD)
First Posted Date
2025-09-09
Last Posted Date
2025-09-16
Lead Sponsor
University of Illinois at Chicago
Target Recruit Count
63
Registration Number
NCT07162363
Locations
🇺🇸

University of Illinois Hospital & Health Sciences System (UI Health), Chicago, Illinois, United States

Cognitive-Motor Training for AD/ADRD Prevention

Not Applicable
Not yet recruiting
Conditions
MCI
Aging
First Posted Date
2025-09-08
Last Posted Date
2025-09-08
Lead Sponsor
University of Illinois at Chicago
Target Recruit Count
46
Registration Number
NCT07160582
Locations
🇺🇸

University of Illinois at Chicago, Chicago, Illinois, United States

UIC Multi-Ethnic DCM Registry

Recruiting
Conditions
Heart Failure
Dilated Cardiomyopathy (DCM)
First Posted Date
2025-08-28
Last Posted Date
2025-08-28
Lead Sponsor
University of Illinois at Chicago
Target Recruit Count
1500
Registration Number
NCT07145138
Locations
🇺🇸

University of Illinois Hospital & Health Sciences, Chicago, Illinois, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 95
  • Next

News

Hydrogel-Based mRNA Cancer Vaccine Platform Shows Promise for Enhanced Immune Response

Researchers at the University of Illinois have developed a macroporous hydrogel-based mRNA cancer vaccine platform that actively recruits dendritic cells to improve vaccine efficiency.

FDA Grants First-Ever Waiver of Clinical Efficacy Studies for Monoclonal Antibody Biosimilars

Professor Sarfaraz K. Niazi has secured the first-ever FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars, fundamentally redefining biological drug development and approval processes.

Breakthrough in Platelet Engineering Opens New Avenues for Targeted Drug Delivery

University of Illinois researchers have successfully applied metabolic glycan labeling to platelets for the first time, overcoming the challenge of engineering these nucleus-free cell fragments.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.